A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : CE / contrast enhancement

[Related PubMed/MEDLINE]
Total Number of Papers: 139
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   CE  (>> Co-occurring Abbreviation)
Long Form:   contrast enhancement
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Contrast Enhancement and Image Quality Influence Two- and Three-dimensional Echocardiographic Determination of Left Ventricular Volumes: Comparison With Magnetic Resonance Imaging. CMR, EF, LV, MI
2019 Contrast enhancement is a prognostic factor in IDH1/2 mutant, but not in wild-type WHO grade II/III glioma as confirmed by machine learning. IDH, MRI, RSF
2019 Contrast-enhancement in supratentorial low-grade gliomas: a classic prognostic factor in the molecular age. ---
2019 Evaluation of the apparent diffusion coefficient in patients with recurrent glioblastoma under treatment with bevacizumab with radiographic pseudoresponse. BVZ, GBM, RANO
2019 Extracellular volume fraction determined by equilibrium contrast-enhanced multidetector computed tomography as a prognostic factor in unresectable pancreatic adenocarcinoma treated with chemotherapy. CA, CEA, ECV, HR, MDCT
2019 FET PET reveals considerable spatial differences in tumour burden compared to conventional MRI in newly diagnosed glioblastoma. FET, FLAIR
2019 High Enhancement Settings for White Light Observation Improves Colorectal Polyp Visibility in Color Difference Value and an Endoscopist's Visibility. CD
2019 High-grade soft-tissue sarcoma: optimizing injection improves MRI evaluation of tumor response. AUROC, NAC, STS
2019 Looking for Lepidic Component inside Invasive Adenocarcinomas Appearing as CT Solid Solitary Pulmonary Nodules (SPNs): CT Morpho-Densitometric Features and 18-FDG PET Findings. SPNs, SPNs
10  2019 Molecular and radiological characterization of Glioblastoma Multiforme using MRI. ADC, GBM
11  2019 Usefulness of diluted contrast medium for test-scanning of infants scheduled for contrast-enhanced cardiovascular computed tomography angiography. CCTA, CM
12  2019 Why is middle cerebral artery plaque augmented by contrast media? A phantom study using middle cerebral arterystenotic silicon model. BB, CE-T1W, MCA
13  2018 Association of gadolinium-enhanced magnetic resonance imaging with hepatic fibrosis and inflammation in primary sclerosing cholangitis. GBCA, IRR, LL, mHAI, MRI, PSC, RL, RLE
14  2018 Contrast-enhanced transoral carotid ultrasonography for the diagnosis and follow-up of extracranial internal carotid artery dissection: A case report. ICAs, TOCU
15  2018 Diagnostic Performance and Interreader Agreement of a Standardized MR Imaging Approach in the Prediction of Small Renal Mass Histology. CI, MR, OR, RCC, SI
16  2018 Differentiation of Seromucinous Borderline Tumor from Serous Borderline Tumor on MR Imaging. AUC, SBT, SI, SMBT, T1WI, T2WI, WHO
17  2018 Efficacy of double inversion recovery magnetic resonance imaging for the evaluation of the synovium in the femoro-patellar joint without contrast enhancement. CET1FS, DIR
18  2018 Increased Delay Between Gadolinium Chelate Administration and T1-Weighted Magnetic Resonance Imaging Acquisition Increases Contrast-Enhancing Tumor Volumes and T1 Intensities in Brain Tumor Patients. NE, NEC, T1W
19  2018 Molecular physiology of contrast enhancement in glioblastomas: An analysis of The Cancer Imaging Archive (TCIA). CEr, ECM, G-CIMP, IPVL
20  2018 Molecular profiles of tumor contrast enhancement: A radiogenomic analysis in anaplastic gliomas. AGs, CGGA, GSEA, MR
21  2018 Segment-specific associations between local haemodynamic and imaging markers of early atherosclerosis at the carotid artery: an in vivo human study. CCA, WSS
22  2018 The diagnostic yield using ultrasound-guided needle-aspiration for subpleural primary lung cancer is not affected by the radiological properties of the lesions resulting from computed tomography. CT, USGNA
23  2018 Thrombus Enhancement Is a Predictor of Clinical Outcome in Acute Ischemic Stroke after Mechanical Thrombectomy. CECT, CT, mRS, MT, NECT
24  2018 TSPO PET with [18F]GE-180 sensitively detects focal neuroinflammation in patients with relapsing-remitting multiple sclerosis. MRI, PRR, RRMS, SUV, SUVR, TSPO
25  2018 Ultrasound for Assessing Disease Activity in IBD Patients: A Systematic Review of Activity Scores. BWT, CD, DS, US, WLS
26  2017 Contrast-enhanced MDCT in patients with pancreatic neuroendocrine tumours: correlation with histological findings and diagnostic performance in differentiation between tumour grades. CT, MDCT, MVD, PNETs
27  2017 Contrast-enhanced ultrasound does not discriminate between community acquired pneumonia and lung cancer. CAP, CEUS, LC
28  2017 Diagnostic value of gadobutrol versus gadopentetate dimeglumine in enhanced MRI of brain metastases. ANOVA, CBR, CER, CNR, Gd-DTPA, MRI, SNR
29  2017 Grading diffuse gliomas without intense contrast enhancement by amide proton transfer MR imaging: comparisons with diffusion- and perfusion-weighted imaging. ADC, APT, APT90, HGGs, LGGs, rCBV, ROC
30  2017 Head-to-Head Comparison of Inflammation and Neovascularization in Human Carotid Plaques: Implications for the Imaging of Vulnerable Plaques. ---
31  2017 Local image variance of 7 Tesla SWI is a new technique for preoperative characterization of diffusely infiltrating gliomas: correlation with tumour grade and IDH1 mutational status. HGG, IDH1, LGG, LIV, SWI
32  2017 MRI-CEST assessment of tumour perfusion using X-ray iodinated agents: comparison with a conventional Gd-based agent. CEST
33  2017 Preoperative Lymph Node Staging by FDG PET/CT With Contrast Enhancement for Thyroid Cancer: A Multicenter Study and Comparison With Neck CT. FDG, LN, PET/CT
34  2017 Relationship between magnetic resonance imaging characteristics and plasmatic levels of MMP2 and MMP9 in patients with recurrent high-grade gliomas treated by Bevacizumab and Irinotecan. HGG
35  2017 Response Assessment in Neuro-Oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma. GBM, RANO, rCBV, TTPs
36  2017 Semi-quantitative evaluation of signal intensity and contrast-enhancement in Modic changes. MCs, ROIs, SI
37  2017 SIFT Based Vein Recognition Models: Analysis and Improvement. EER, PR, SIFT
38  2017 Soft-Tissue Tumor Contrast Enhancement Patterns: Diagnostic Value and Comparison Between Ultrasound and MRI. ---
39  2016 Comparison of small animal CT contrast agents. CAs, CT, mRNA, TNF
40  2016 Early Detection of Malignant Transformation in Resected WHO II Low-Grade Glioma Using Diffusion Tensor-Derived Quantitative Measures. AUC, CNR, DTI, MT
41  2016 Hue-preserving and saturation-improved color histogram equalization algorithm. HE
42  2016 Imaging-genomics reveals driving pathways of MRI derived volumetric tumor phenotype features in Glioblastoma. ED, GBM, MRI, NE, TV
43  2016 Non-Infectious Peri-Electrode Edema and Contrast Enhancement Following Deep Brain Stimulation Surgery. DBS, DRAAEP, PD, STN
44  2016 Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma. ADC, FLAIR, HGG, OS, PFS, RSI
45  2015 Clinical Significance of Discrepancy between Arterial Spin Labeling Images and Contrast-enhanced Images in the Diagnosis of Brain Tumors. ASL, HGG, LGG, MR, PCNSL
46  2015 Colour contrasting between tissues predicts the resection in 5-aminolevulinic acid-guided surgery of malignant gliomas. 5-ALA, AUC, CR, HGG, MRI
47  2015 Contrast-enhanced MRI of the temporomandibular joint: findings in children without juvenile idiopathic arthritis. JIA, MRI, SI, T1W, T2W, TMJ
48  2015 Enhancement patterns of intrahepatic mass-forming cholangiocarcinoma at multiphasic computed tomography and magnetic resonance imaging and correlation with clinicopathologic features. CT, EP, HCC, IMCC, MRI
49  2015 Extent of Contrast Enhancement on Non-Enhanced Computed Tomography after Intra-Arterial Thrombectomy for Acute Infarction on Anterior Circulation: As a Predictive Value for Malignant Brain Edema. CEAR, IAT, NECT
50  2015 Prognostic implication of progression pattern after anti-VEGF bevacizumab treatment for recurrent malignant gliomas. VEGF
51  2015 Rosette-forming Glioneuronal Tumor: Rare Case Presented with Spontaneous Disappearance of Contrast Enhancement. ETV, MR, RGNT
52  2015 Synthesis, relaxation properties and in vivo assessment of a carborane-GdDOTA-monoamide conjugate as an MRI blood pool contrast agent. BPCA, CB-GdDOTA-MA, HSA, MRA, p.i
53  2015 The prognostic value of gadolinium-enhanced magnetic resonance imaging in acute invasive fungal rhinosinusitis. AIFRS, Gd, LoCE, MRI
54  2015 [Features of clinical presentation, pathology and magnetic resonance or computed tomography imaging for ocular lymphoma]. MALT, MRI/CT
55  2014 18F-FDG PET and MR imaging associations across a spectrum of pediatric brain tumors: a report from the pediatric brain tumor consortium. BSGs, OS, PFS
56  2014 Coronary vessel wall contrast enhancement imaging as a potential direct marker of coronary involvement: integration of findings from CAD and SLE patients. CAD, CMR, CNR, IQR, SLE
57  2014 Hounsfield unit values of retropharyngeal abscess-like lesions seen in Kawasaki disease. CT, HUs, KD
58  2013 Albumin-binding MR blood pool contrast agent improves diagnostic performance in human brain tumour: comparison of two contrast agents for glioblastoma. CNR, SNR
59  2013 Black blood MRI in suspected large artery primary angiitis of the central nervous system. PACNS
60  2013 Comparison of DSC-MRI post-processing techniques in predicting microvascular histopathology in patients newly diagnosed with GBM. DSC, GBM
61  2013 Contrast-enhanced multidetector computerized tomography for odontogenic cysts and cystic-appearing tumors of the jaws: is it useful? CT
62  2013 Correlation between response to chemotherapy with concomitant bevacizumab for hepatic metastasis of colorectal cancer and degree of enhancement using contrast-enhanced computed tomography. BV, CT
63  2013 CT arthrography of the wrist using a novel, mobile, dedicated extremity cone-beam CT (CBCT). ACC, CBCT, LTL, Se, Sp, TD, TFCC
64  2013 Dosimetric effect of CT contrast agent in CyberKnife treatment plans. CK, CT, DVHs, MC, OARs, SABR, TPS
65  2013 Early MRI changes in glioblastoma in the period between surgery and adjuvant therapy. EPMR, PAMR
66  2013 Enhancement in a brain glioma model: a comparison of half-dose gadobenate dimeglumine versus full-dose gadopentetate dimeglumine at 1.5 and 3 T. CNR, SNR
67  2013 Integration method of 3D MR spectroscopy into treatment planning system for glioblastoma IMRT dose painting with integrated simultaneous boost. 3DCRT, IMRT, MRSI, SIB, TPS
68  2013 Magnified and enhanced computed virtual chromoendoscopy in gastric neoplasia: a feasibility study. CVC, HGD, LGD, SE, TE
69  2013 Texture enhanced histogram equalization using TV- L image decomposition. TV
70  2013 Transferrin-coated gadolinium nanoparticles as MRI contrast agent. Gd-DTPA, HSA NPs
71  2013 Warming effect on miriplatin-lipiodol suspension as a chemotherapeutic agent for transarterial chemoembolization for hepatocellular carcinoma: preliminary clinical experience. CT, HCC, MPT-LPD, TACE
72  2013 [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma. LBRs, WHO
73  2012 Accuracy of MRI with an endorectal coil for staging endometrial cancer. FS, MRI, T2W, TSE
74  2012 Contrast enhancement kinetics of normal breast parenchyma in dynamic MR mammography: effects of menopausal status, oral contraceptives, and postmenopausal hormone therapy. HT, MRM, OC
75  2012 Contrast enhancement of the brain by folate-conjugated gadolinium-diethylenetriaminepentaacetic acid-human serum albumin nanoparticles by magnetic resonance imaging. FA, Gd-DTPA, HSA, MRI, NPs
76  2012 Densitometric CT evaluation of acute and chronic thromboembolic filling defects of the pulmonary arteries before and after contrast injection. CT, Ht, HU, PE
77  2012 In vivo measurement of plaque neovascularisation and thermal heterogeneity in intermediate lesions of human carotid arteries. CEUS, MR
78  2012 Infarct tissue characteristics of patients with versus without early revascularization for acute myocardial infarction: a contrast-enhancement cardiovascular magnetic resonance imaging study. CMR, ESV, LV, MI, WMSI
79  2012 Metabolic profile of PML lesions in patients with and without IRIS: an observational study. Cho, Cr, IRIS, mI, NAA, PML, PML-P, PML-S
80  2012 Potential role of combined FDG PET/CT & contrast enhancement MRI in a rectal carcinoma model with nodal metastases characterized by a poor FDG-avidity. ---
81  2012 Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging. DSC, DWI, GBM, NE
82  2012 Spontaneous modifications of contrast enhancement in childhood non-cerebellar pilocytic astrocytomas. MRI, n-C PA, PA
83  2012 SU-E-T-524: The Effect of CT Contrast on CyberKnife Treatment Planning. CK, MC
84  2012 The value of (18)F-FDG PET/CT in the assessment of active idiopathic retroperitoneal fibrosis. CRP, ESR, IRF, MV
85  2011 Differentiation between benign and malignant adrenal mass using contrast-enhanced ultrasound. ---
86  2011 Evaluation of a fibrin-binding gadolinium chelate peptide tetramer in a brain glioma model. ---
87  2011 Is contrast enhancement required to visualize a known breast tumor in a pre-operative CT scan? ---
88  2011 Real-time contrast enhancement to improve speech recognition. ---
89  2011 Stripe-like increase of rCBV beyond the visible border of glioblastomas: site of tumor infiltration growing after neurosurgery. DSC, GBM, rCBV, ROI, SS, WI
90  2011 Value of 1H-magnetic resonance spectroscopy chemical shift imaging for detection of anaplastic foci in diffusely infiltrating gliomas with non-significant contrast-enhancement. CSI, DIG, Met, PET
91  2010 Evaluation of gadodiamide versus gadobutrol for contrast-enhanced MR imaging in a rat brain glioma model at 1.5 and 3 T. CNR
92  2010 Microvascular leakage and contrast enhancement as prognostic factors for recurrence in unfavorable low-grade gliomas. CI, MRI, MVL, PFS, pts, rCBV, ULGG
93  2010 Novel image-enhanced endoscopy with i-scan technology. SE, TE
94  2009 Brain tumor enhancement in magnetic resonance imaging: dependency on the level of protein binding of applied contrast agents. CNR
95  2009 Development of a method to quantitatively monitor the effect of inhibition of nitric oxide synthase on tumour vascular activity using dynamic contrast-enhanced computed tomography. DCE-CT, L-NNA, NOS, TBV
96  2009 Necrotizing fasciitis versus pyomyositis: discrimination with using MR imaging. NF, PM
97  2009 Prognostic significance of imaging contrast enhancement for WHO grade II gliomas. ---
98  2009 Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma. DWI, MRSI, PWI, RT
99  2008 Evaluation of magnetic resonance colonography at 3.0 Tesla regarding diagnostic accuracy and image quality. 3D-FLASH, CC, iPAT, MR, SD, VIBE
100  2008 Increased fronto-temporal perfusion in bipolar disorder. CBV, PWI